Evidence map›Paper›PMID 39760531›Full record

ArticleClinical and translational science2025

Prediction of Cisplatin-Induced Acute Kidney Injury Using an Interpretable Machine Learning Model and Electronic Medical Record Information.

Kaori Ambe, Yuka Aoki, Miho Murashima, Chiharu Wachino, Yuto Deki, Masaya Ieda, Masahiro Kondo, Yoko Furukawa-Hibi, Kazunori Kimura, Takayuki Hamano and 1 more

Abstract read
In one paragraph

Article in Clinical and translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kaori AmbeDepartment of Regulatory Science, Nagoya City University Graduate School of Pharmaceutical Sciences, Nagoya, Japan.ORCID 0000-0003-4387-9134
Yuka AokiDepartment of Regulatory Science, Nagoya City University Graduate School of Pharmaceutical Sciences, Nagoya, Japan.
Miho MurashimaDepartment of Nephrology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.ORCID 0000-0002-2923-0438
Chiharu WachinoNagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Yuto DekiDepartment of Regulatory Science, Nagoya City University Graduate School of Pharmaceutical Sciences, Nagoya, Japan.
Masaya IedaDepartment of Regulatory Science, Nagoya City University Graduate School of Pharmaceutical Sciences, Nagoya, Japan.
Masahiro KondoNagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Yoko Furukawa-HibiNagoya City University Graduate School of Medical Sciences, Nagoya, Japan.ORCID 0000-0002-2126-5652
Kazunori KimuraNagoya City University Graduate School of Medical Sciences, Nagoya, Japan.ORCID 0000-0002-2473-4776
Takayuki HamanoDepartment of Nephrology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.ORCID 0000-0002-2100-9106
Masahiro TohkinDepartment of Regulatory Science, Nagoya City University Graduate School of Pharmaceutical Sciences, Nagoya, Japan.ORCID 0000-0002-2937-8926

Funding

Grant-in-Aid for Research in Nagoya City University 2121103JSPS KAKENHI JP23K06133
6 · The paper itself

Abstract

Predicting cisplatin-induced acute kidney injury (Cis-AKI) before its onset is important. We aimed to develop a predictive model for Cis-AKI using patient clinical information based on an interpretable machine learning algorithm. This single-center retrospective study included hospitalized patients aged ≥ 18 years who received the first course of cisplatin chemotherapy from January 1, 2011, to December 31, 2020, at Nagoya City University Hospital. Cis-AKI-positive patients were defined using the serum creatinine criteria of the Kidney Disease Improving Global Outcomes guideline within 14 days of the last day of cisplatin administration in the first course. Patients who received cisplatin but did not develop AKI were considered negative. The CatBoost classification model was constructed with 29 explanatory variables, including laboratory values, concomitant medications, medical history, and cisplatin administration information. In total, 1253 patients were included, of whom 119 developed Cis-AKI (9.5%). The median time of AKI onset was 7 days, and the interquartile range was 5-8 days. The mean ± standard deviation of the total cisplatin dose in the initial treatment was 77.9 ± 27.1 mg/m

Indexed as

Acute Kidney InjuryCisplatinElectronic Health RecordsMachine LearningAdultAgedAntineoplastic AgentsCreatinineFemaleHumansMaleMiddle AgedRetrospective StudiesAntineoplastic AgentsCisplatinCreatinineacute kidney injurycisplatinelectronic medical recordmachine learning

Identifiers

PMID39760531
PMCPMC11702448

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.